emedastinum - Resultados da pesquisa

União Europeia - português - EMA (European Medicines Agency)

emadine

immedica pharma ab - emedastine difumarate - conjuntivite, alergica - oftalmológicos - tratamento sintomático da conjuntivite alérgica sazonal.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

clemastinum wzf ip 2 mg/2 ml solução injetável

inovemed - produtos farmacêuticos, lda. - clemastina - solução injetável - 2 mg/2 ml - clemastina, fumarato 1.34 mg/ml - clemastine - n/a - duração do tratamento: curta ou média duração

União Europeia - português - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agentes antineoplásicos - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

União Europeia - português - EMA (European Medicines Agency)

yescarta

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agentes antineoplásicos - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.